Zacks Investment Research upgraded shares of Synthorx (NASDAQ:THOR) from a hold rating to a buy rating in a research note issued to investors on Thursday, Zacks.com reports. The brokerage currently has $17.00 price target on the medical instruments supplier’s stock.
According to Zacks, “Synthorx Inc. is a biopharmaceutical company which focuses on cancer and autoimmune disorders. The company’s product pipeline consists of THOR-707, IL-2 autoimmune synthorin, IL-10 synthorin and IL-15 synthorin which are in clinical stage. Synthorx Inc. is based in La Jolla, CA. “
Separately, HC Wainwright reissued a buy rating on shares of Pulse Biosciences in a report on Wednesday, May 1st. Five equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and an average price target of $22.67.
Synthorx (NASDAQ:THOR) last released its earnings results on Tuesday, April 30th. The medical instruments supplier reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.03). On average, sell-side analysts forecast that Synthorx will post -1.57 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC acquired a new position in Synthorx during the 4th quarter worth approximately $38,559,000. Strs Ohio acquired a new position in Synthorx during the 1st quarter worth approximately $38,000. Matisse Capital boosted its position in Synthorx by 16.9% during the 1st quarter. Matisse Capital now owns 64,333 shares of the medical instruments supplier’s stock worth $1,310,000 after acquiring an additional 9,300 shares during the last quarter. Finally, Emory University acquired a new position in Synthorx during the 1st quarter worth approximately $2,439,000. 66.08% of the stock is currently owned by institutional investors.
Synthorx, Inc, a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor.
Recommended Story: Do back-end load funds outperform no-load funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with MarketBeat.com's FREE daily email newsletter.